Viewing nowEmplazine 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Dongkook Pharmaceutical Co., Ltd.

MFDS item code 202102601 · Approved 2021.03.25 · Insurance code 653405980
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in adult patients with Type 2 diabetes to assist along with dietary and exercise therapy to improve blood glucose control. It can be administered as monotherapy, but if blood glucose control is insufficient, it should be used in combination with metformin or other antidiabetic agents. Specifically, it can be combined with metformin, pioglitazone, sulfonylureas, insulin, DPP-4 inhibitors, etc., to increase efficacy. It must be used cautiously in Type 2 diabetes patients with cardiovascular disease, and it is recommended to refer to relevant clinical trial information. It effectively improves blood glucose control tailored for various circumstances.
The recommended dose of this medicine for monotherapy and add-on combination therapy with other blood glucose-lowering agents such as insulin is 10 mg once daily. If additional glycemic control is needed and 10 mg of this medicine is well tolerated, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be administered with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take twice the dose in one day. Special Populations •Patients with renal impairment No dosage adjustment is required in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with a glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently glomerular filtration rate less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dosage adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. •Elderly patients No dosage adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of treatment with this medicine is not recommended in elderly patients 85 years of age or older because clinical experience is limited (see Precautions for Use, 4. General Precautions)
This medication should not be administered to certain patients. First, patients who are allergic to the main component or any ingredients of this medication should not take it. Also, it should not be used in patients with Type 1 diabetes or diabetic ketoacidosis. Patients with severely decreased kidney function with a glomerular filtration rate (GFR) less than 30 mL/min/1.73m2, those with end-stage kidney disease, or those on dialysis should not take this medication. This drug contains lactose, so it should not be administered to patients with lactose intolerance, galactose intolerance, or congenital lactase deficiency. Caution should be taken when administering to patients with slightly reduced kidney function. It is advisable not to initiate this medication in patients with a GFR less than 60 mL/min/1.73m2, and if administered, the dose should be adjusted. If GFR continues to drop below 45 mL/min/1.73m2, the medication should be discontinued. In patients with end-stage kidney disease or those undergoing dialysis, the effectiveness of this drug is not expected, and it should not be used. In patients with mild to moderate heart failure, this medication should be used with caution; it is not recommended in patients with severe heart failure. If using glucose-lowering agents like insulin or sulfonylureas together, the risk of hypoglycemia may increase, so the dose of those agents may need to be reduced when used in conjunction with this medication. During treatment with this medication, symptoms of hypoglycemia may occur, so blood glucose should be monitored regularly, and if any abnormal symptoms arise, immediate consultation with healthcare professionals is advised. There may be an increased risk of genital infections or urinary tract infections, so early treatment should be sought if infection symptoms develop. Due to possible fluid loss in the body, dehydration, and hypotension may occur; thus, caution is needed especially for elderly patients or those with low blood pressure. Rarely, severe metabolic disorders known as ketoacidosis may occur, so if symptoms such as vomiting, abdominal pain, or difficulty breathing arise, immediate medical attention should be sought. Women who are pregnant or planning to become pregnant should avoid taking this medication, and it should also not be used while breastfeeding. This medication has not been confirmed for safety and efficacy in children under 18 years of age. No specific toxicity has been reported in case of overdose, but if suspected, appropriate treatment should be obtained immediately from a medical institution. This medication should be kept out of the reach of children, and transferring it to another container should be avoided as it may affect its quality. Caution is required when driving or operating machinery due to the risk of hypoglycemia, especially if taking this medication with insulin or sulfonylureas. Diabetic patients should prioritize regular foot care, and care should be taken to prevent wounds or infections on the feet while using this medication. If pain, swelling, or redness occurs around the perineum, it could be a serious infection known as perineal necrotizing fasciitis, and immediate medical attention should be sought. This medication can interact with other medications, so it is important to inform healthcare professionals of all medications being taken and undergo regular evaluations.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 30 degrees Celsius to preserve the medication's efficacy.
Light yellow, biconvex oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Dongkook Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.